98%
921
2 minutes
20
Background: Diffuse large B-cell lymphoma (DLBCL) constitutes 30% of all non-Hodgkin's lymphomas. It can present as a nodal disease or as an extra nodal disease. Based on the site of origin, extra nodal DLBCL (EN-DLBCL) may have a distinct clinical outcome. Apart from the site of origin, factors including demographics, stage, and presence of any other primary malignancy also affect the outcome. The purpose of our study was to characterize prognostically distinct groups based on the site of presentation of EN-DLBCL.
Methods: We used 18 registries in Surveillance, Epidemiology, and End Results database to identify the patients with EN-DLBCL for 2000 - 2015 with last follow-up till December 31, 2018. A total of 30,290 EN-DLBCL patients were selected and categorized based on 13 broad sites grouping. Demographic variables were summarized. We did overall survival analysis with univariate and multivariate Cox-proportional hazard modeling. Short-term survival trend was calculated as well.
Results: The percentage of EN-DLBCL of all DLBCLs is 34.48%. EN-DLBCL was comparatively seen more in males (54.94%) and non-Hispanic whites (71.52%). In terms of clinical characteristics, patients with EN-DLBCL were mostly diagnosed at age ≥ 60 years (66.11%), early stage (69.33%), and presentation as first primary cancer (81.89%). A higher risk of mortality was seen in non-Hispanic black (hazard ratio (HR) 1.36), with late age of onset (HR 2.69), late stage at presentation (HR 1.42), and with history of other malignancy (HR 1.29). Compared to the intestinal tract, the risk of overall mortality was higher in individuals with involvement of nervous system (HR 1.85), pancreas and hepatobiliary system (HR 1.22), and respiratory system (HR 1.18) and the best outcomes were seen in heart and mediastinal site (HR 0.58) of DLBCL.
Conclusion: Based upon our population-based study, we conclude that primary site of presentation of EN-DLBCL is an important prognostic factor with significant difference in survival based on histological and epidemiological characteristics.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076143 | PMC |
http://dx.doi.org/10.14740/jh984 | DOI Listing |
Med Int (Lond)
August 2025
Department of Oncology, Combined Military Hospital/National University of Medical Sciences, Rawalpindi 46000, Pakistan.
Follicular dendritic cell sarcoma (FDCS) is a rare tumour derived from dendritic cells located in B-follicles that play a pivotal role in the adaptive immune response. Surgery is the mainstay of treatment for localized disease; however, the management of unresectable or advanced disease is less well-defined. To date, to the best of our knowledge, there is no established or preferred chemotherapeutic regimen, although a number of regimens (primarily used in lymphomas and sarcomas) have been utilized with suboptimal outcomes.
View Article and Find Full Text PDFEur J Surg Oncol
August 2025
Department of Surgery, Skåne University Hospital, Malmö, Sweden; Department of Clinical Sciences, Lund University, Lund, Sweden. Electronic address:
Introduction: Tumor deposits are an important negative prognostic factor for long-term oncological outcomes in colorectal cancer patients, independent of lymph node status. Several novel models have been proposed to further integrate tumor deposits into the TNM-staging system, but their comparative performance remains unclear. The aim of this study was to identify, compare and validate novel prognostic models incorporating tumor deposits for N-stage classification.
View Article and Find Full Text PDFBurkitt lymphoma (BL) is an aggressive B-cell malignancy characterized by rapid progression and MYC gene translocations. Jejunal involvement in BL is rare compared to more common sites like the lymph nodes and central nervous system. Diagnosing BL in the jejunum is particularly challenging as it can mimic other gastrointestinal conditions, necessitating a high index of suspicion and histopathological confirmation.
View Article and Find Full Text PDFOral Oncol
August 2025
Department of Otolaryngology - Head and Neck Surgery, St. James' Hospital, Dublin, Ireland; University of Dublin, Trinity College, Dublin, Ireland.
Introduction: The lymph-node yield and the lymph-node ratio have emerged as important prognostic tools for head and neck cancer. These metrics are an index of disease burden, but also of quality standards. The objective of the present study was to examine the impact of different lymph-node yield cut-offs and the lymph-node ratio on 10-year recurrence-free interval and overall-survival.
View Article and Find Full Text PDFRecenti Prog Med
September 2025
Uoc Medicina, Azienda Ulss 6 Euganea, Camposampiero (Padova).
Diffuse large B-cell lymphomas (DLBCLs) represent one of the most common and aggressive forms of non-Hodgkin lymphoma (NHL), characterized by rapid B-cell growth and a significantly high risk of relapse or refractoriness. The clinical course for these patients is long and complicated with a sometimes dismal prognosis, and the therapeutic approach must include effective and innovative chemotherapeutic treatments. The therapeutic strategies for DLBCLs in recent years has seen considerable pharmacological enrichment, including drug-conjugated antibodies such as polatuzumab vedotin.
View Article and Find Full Text PDF